MedTrace Logo

Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia

NCT00244231 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2007-03-01

No results posted yet for this study

Summary

To assess the efficacy and safety of Nidadd (extended-release niacin) in patients with hyperlipidemia.

Conditions

Interventions

DRUG

Nidadd

Sponsors & Collaborators

  • Genovate Biotechnology Co., Ltd.,

    lead INDUSTRY

Principal Investigators

  • Jen-Der Lin, M.D. · Chang GungMemorial Hospital

  • Jawl-Shan Huang, M.D. · Chang Gung Memorial Hospital

  • Miaw-jene Liou, M.D. · Chang Gung Memorial Hospital

  • Chih-ching Wang, M.D. · Chang Gung Memorial Hospital

  • Yi-Jen Hung, M.D. · Tri-Service General Hospital

  • Chang-Hsun Hsieh, M.D. · Tri-Service General Hospital

  • Chih-Tsueng He, M.D. · Tri-Service General Hospital

  • Huey-Herng Sheu, M.D. · Taichung Veterans General Hospital

  • Yu-Ling Lin, M.D. · Taichung Veterans General Hospital

  • Shih-Yi Lin, M.D. · Taichung Veterans General Hospital

  • Yih-Jing Tang, M.D. · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2005-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244231 on ClinicalTrials.gov